Immune checkpoint protein VISTA can directly turn off T-cells during immunotherapy, study finds

FHS
May 17, 2024
6:23 pm

A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.

Why do people with obesity, but without diabetes, start taking semaglutide?

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

January 22, 2025

CDC updates pain care guidelines for clinicians

Pain affects the lives of millions of Americans every day and improving pain care and the lives of patients with pain is a public health

November 11, 2024

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

Nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) did not improve overall survival (OS) and

August 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.